NASD · Healthcare · Biotechnology · USA
Korsana Biosciences Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Korsana Biosciences Inc stock.
Overvalued: intrinsic value $0.08 per share, market price $34.98, margin of safety -42551.7% (as of 2026-09-22).
Its liquidation floor, current assets minus every liability, values the shares at $0.08; the price of $34.98 is 42552% above that value.
Leak Score: 26/100 on 7 of 12 signals (not enough of the checklist to rate).
101 more in this industry show a wider margin of safety.
KRSA is overvalued (as of the 2026-09-22 close). Its liquidation floor, current assets minus every liability, values the shares at $0.08; the price of $34.98 is 42552% above that value.
$0.08 per share (as of the 2026-09-22 close), against a market price of $34.98. That is a margin of safety of -42551.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
26 out of 100, on 7 of 12 value investing signals. Too much of the checklist is missing for a rating: the remaining signals need filings this company has not published yet, so treat the score as a partial read.